9 unchanged sentences
• The Company may not realize revenue levels from its InteliSwab® COVID-19 Rapid Test consistent with prior years.
−Removed: • The COVID-19 pandemic continues to cast uncertainty over the Company's consolidated results of operations, financial position and cash flows, while the consequences of COVID-19 and the governmental response to contain the pandemic and pandemic-related macroeconomic impacts could negatively affect the Company's operations and share price.
• Marketing of the Company's COVID-19 tests and collection kits under EUAs from the FDA is subject to certain limitations and it is required to maintain compliance with the terms of the EUA, among other things, and the continuance of the EUAs is subject to government discretion.
• If acceptance and adoption of oral fluid testing and collection products does not continue, the Company's future results may suffer.
−Removed: • The Company expects to face increasing competition from other providers of diagnostic tests, sample collection products and molecular laboratory services.
+Added: • The Company expects to face increasing competition from other providers of diagnostic tests, and sample collection products.
• The Company's inability to expand international sales could adversely affect its business and results of operations.
8 unchanged sentences
• Customer concentration creates risk for the Company's business.
+Added: • The Company is subject to risks related to government funding and customer ordering.
• Acquisitions or investments may not generate the expected benefits and could disrupt the Company's ongoing business, distract its management, increase its expenses and adversely affect its business.
23 unchanged sentences
Changes in the Genomics Market May Adversely Affect the Company's Business .
−Removed: The genomics market has been the largest component of the Company's overall molecular sample management solutions business for some time and the major drivers of this market have been the consumer genomics segment, which offers products and services to consumers to provide them with personalized health and genealogical information, and the disease risk management segment which offers genetic testing through physicians for a variety of applications including prenatal testing, risk screening and pharmacogenomics.
+Added: The genomics market has been the largest component of the Company's overall sample management solutions business for some time and the major drivers of this market have been the consumer genomics segment, which offers products and services to consumers to provide them with personalized health and genealogical information, and the disease risk management segment which offers genetic testing through physicians for a variety of applications including prenatal testing, risk screening and pharmacogenomics.
The ancestry portion of the consumer genomics market may be maturing and the Company's sales to customers with offerings in this market have been volatile.
−Removed: The Company's genomics revenues have also been volatile due to changes in promotional strategies and purchasing patterns by certain customers which serve
−Removed: the consumer ancestry and genetic testing market and cost cutting and de-stocking efforts at some of the Company's disease risk management customers.
+Added: The Company's genomics revenues have also been volatile due to changes in promotional strategies and purchasing patterns by certain customers which serve the consumer ancestry and genetic testing market and cost cutting and de-stocking efforts at some of the Company's disease risk management customers.
These trends in the ancestry testing market may continue and revenues in this market may continue to be volatile.
6 unchanged sentences
The Company's future success will depend, in part, on the market acceptance, and the timing of such acceptance, of products such as InteliSwab ® , OraQuick ® HIV Self-Test, OraQuick ® Ebola test and OMNIgene ® • GUT product offerings, and other new products or technologies that may be developed or acquired.
−Removed: In addition, the Company's future revenues will depend on market acceptance of new uses for the Company's saliva collection products, including for COVID-19 testing, and the Company's new service offerings, such as the microbiome laboratory testing and analytical services it provides through Diversigen.
+Added: In addition, the Company's future revenues will depend on market acceptance of new uses for the Company's saliva collection products, and the Company's new service offerings, such as Syphilis Health Check ® and OraQuick ® HCV Self-Test.
To commercially market new uses of the Company's products and to achieve market acceptance, it will likely be required to undertake clinical studies to validate the new uses for its products and spend significant funds to complete product development and clinical studies and then undertake substantial marketing efforts to inform potential customers and the public of the existence and perceived benefits of these products and services.
6 unchanged sentences
In addition, other products that compete with the Company's may achieve 510(k) clearance earlier than the Company's do, providing market advantages.
−Removed: The Company May Not Realize Revenue Levels From its InteliSwab® COVID-19 Rapid Test Consistent With Prior Years .
−Removed: The Company has experienced significant demand for its InteliSwab ® COVID-19 Rapid Test;
−Removed: however, the Company expects a significant decline in revenues from InteliSwab ® COVID-19 Rapid Test sales in 2024.
−Removed: While there are still periods of increased COVID-19 prevalence, the public health emergency declarations related to COVID-19 ended on May 11, 2023.
−Removed: The Company has seen a reduction in the prevalence of COVID-19 since the height of the pandemic, and the Company's revenues relating to the Company's COVID-19 testing products have declined, and it expects they will continue to decline in the future if the prevalence of COVID-19 remains low.
+Added: The Company Expects Revenue Levels From its InteliSwab® COVID-19 Rapid Test to Continue to Decline .
+Added: The Company experienced a significant decline in revenues from InteliSwab ® COVID-19 Rapid Test sales in 2024 and expects revenues to continue to decline in 2025.
+Added: The Company has seen a reduction in the prevalence of COVID-19 since the height of the pandemic, particularly following the expiration of the public health emergency declarations related to COVID-19 in mid-2023.
+Added: The Company's revenues relating to the Company's COVID-19 testing products have declined, and it expects they will continue to decline in the future if the prevalence of COVID-19 remains low.
Further, if the COVID-19 pandemic becomes a seasonal virus or experiences fluctuations in prevalence, the Company could experience fluctuations in its revenues associated with its InteliSwab® COVID-19 Rapid Tests.
−Removed: While there is still demand for COVID-19 testing products, there is no guarantee that current or anticipated demand will continue, or if demand does continue, that the
−Removed: Company will be able to produce its InteliSwab® COVID-19 Rapid Test in quantities to meet the demand.
+Added: While there is still limited demand for COVID-19 testing products, there is no guarantee that current or anticipated demand will continue, or if demand does continue, that the Company will be able to produce its InteliSwab® COVID-19 Rapid Test in quantities to meet the demand.
A significant decline in demand for the InteliSwab ® COVID-19 Rapid Test without a corresponding increase in the Company's other businesses could have a material, adverse effect on the Company's results of operations, cash flow and financial position.
−Removed: The COVID-19 Pandemic Continues to Cast Uncertainty Over the Company's Consolidated Results of Operations, Financial Position and Cash Flows, While the Consequences of COVID-19 and the Governmental Response to Contain the Pandemic and Pandemic-Related Macroeconomic Impacts Could Negatively Affect the Company's Operations and Share Price .
−Removed: Although the Company has experienced heavy demand for its InteliSwab ® tests and certain specimen collection devices for use in COVID-19 molecular testing as a result of the COVID-19 pandemic, which has had a positive impact on the Company's performance, the duration and level of the demand for COVID-19 testing is highly uncertain.
−Removed: The Company believes the COVID-19 pandemic's continued impact on its consolidated results of operations, financial position and cash flows will be primarily driven by;
−Removed: (i) the severity and duration of the COVID-19 pandemic;
−Removed: (ii) the COVID-19 pandemic's impact on the U.S.
−Removed: healthcare system and the U.S.
−Removed: (iii) the timing, scope and effectiveness of federal, state and local governmental responses to the COVID-19 pandemic, including the development and deployment of vaccine, and (iv) the COVID-19 pandemic's impact on global clinics, research markets and global logistics.
−Removed: Each of these factors are difficult to predict and the nature, length and severity of any adverse consequences as a result of any given factor are uncertain.
−Removed: Management has closely monitored the impact of the COVID-19 pandemic, with a focus on the health and safety of the Company's employees and business continuity.
−Removed: In response to, or as a result of, the COVID-19 pandemic and emergence of variants, the Company the Company may experience, among other things, voluntary or mandated temporary closures of one or more of its facilities;
−Removed: temporary or long-term labor shortages;
−Removed: temporary or long-term adverse impacts on its supply chain and distribution channels;
−Removed: the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from its facilities;
−Removed: and required reallocation or adjustment of resources, which may impact the its business plans and product offerings.
−Removed: In addition, the direct or indirect impacts of COVID-19 may extend to disrupt the Company's suppliers, partners, manufacturers, customers and other stakeholders, which in turn could materially adversely affect the Company's business, results of operations or financial condition.
−Removed: Any change or disruption in operations could impact and have a material adverse effect on the Company's operations and/or results from operations.
−Removed: In addition, the re-introduction of voluntary or mandated efforts to slow the spread of COVID-19 could impact the Company's operations and sales.
−Removed: If portions or all of the Company's, its partners’, or its customer’s operations are disrupted or suspended as a result of preventative or reactionary measures in response to the ongoing spread of COVID-19, it could have a material adverse impact on the Company's profitability, results of operations, financial condition and share price.
−Removed: Further, there continue to be significant economic and social impacts of the COVID-19 pandemic, including rising inflation rates, continued levels of higher unemployment, and market volatility, among other impacts;
−Removed: any of which may have an impact on consumer behavior, including use of the Company's products.
−Removed: Given the uncertainties associated with the COVID-19 pandemic, including the uncertainty surrounding the remaining duration and outcome, COVID-19 variants and vaccine efficacy, the Company is unable to estimate the full impact of the COVID-19 pandemic on its business, financial condition, results of operations, and/or cash flows;
−Removed: however, the impact could be material.
Marketing of the Company's COVID-19 Tests and Collection Kits Under EUAs from the FDA Is Subject To Certain Limitations and the Company Is Required To Maintain Compliance with the Terms of the EUA, Among Other Things, and the Continuance of the EUAs Is Subject To Government Discretion.
−Removed: On February 4, 2020, the HHS issued a declaration that the threat to public health posed by COVID-19 justifies the emergency use of unapproved in vitro diagnostics for the detection or diagnosis of SARS-CoV-2.
+Added: In early 2020, the HHS issued a declaration that the threat to public health posed by COVID-19 justifies the emergency use of unapproved in vitro diagnostics for the detection or diagnosis of SARS-CoV-2.
Under Section 564 of the FDCA, because HHS has issued this declaration, the FDA Commissioner is authorized to issue EUAs to permit certain developers of SARS-CoV-2 diagnostics to begin offering the tests for detection and diagnosis of COVID-19 without having completed the normally applicable FDA review and clearance or approval process for marketing authorization (with the related standards that would apply to demonstrate safety and effectiveness).
11 unchanged sentences
If that were to occur, then in order to market the Company's diagnostic products or collection kits for the purpose of detecting COVID-19 the Company would be required to obtain the necessary regulatory clearances or approvals and be subject to the full and usual regulatory obligations for device manufacturers, including the QSR under 21 CFR Part 820.
−Removed: It is possible that the Company may not be able to obtain those clearances or approvals in a timely manner, or at all, and that one or more of OraSure's competitors may obtain the necessary clearances or approvals for their products before it does.
+Added: It is possible that the Company may not be able to obtain those clearances or approvals in a timely manner, or at all, and that one or more of OraSure's competitors may obtain the necessary clearances or approvals for their products before the Company does.
If Acceptance and Adoption of Oral Fluid Testing and Collection Products Does Not Continue, the Company's Future Results May Suffer.
−Removed: The Company has made significant progress in gaining acceptance of oral fluid testing products, particularly for (i) HIV testing in the public health, hospital, insurance and other markets, and (ii) drugs-of-abuse testing in the workplace and criminal justice markets.
−Removed: Its subsidiary, DNAG, has also made significant progress in gaining acceptance of oral fluid collection products that are used with molecular testing applications including testing for SARS-CoV-2.
+Added: The Company has made significant progress in gaining acceptance of oral fluid testing products, particularly for HIV testing in the public health, hospital, insurance and other markets.
However, the degree of acceptance for these products is uncertain, and one or more markets may resist the adoption of oral fluid products as a replacement for other testing or collection methods in use today.
3 unchanged sentences
The Company's future sales will depend, in part, on the Company's ability to expand market acceptance of rapid point-of-care testing by physicians, other healthcare providers and consumers and successfully compete against laboratory testing methods and products.
−Removed: Even if the Company can demonstrate that its products are more cost effective, save time, or have better performance or other benefits, physicians, other healthcare providers and consumers may resist changing to rapid point-of-care tests and instead may choose to obtain diagnostic results through laboratory tests.
+Added: Even if the Company can
+Added: demonstrate that its products are more cost effective, save time, or have better performance or other benefits, physicians, other healthcare providers and consumers may resist changing to rapid point-of-care tests and instead may choose to obtain diagnostic results through laboratory tests.
The Company's failure to achieve and expand market acceptance of its rapid point-of-care diagnostic tests with customers would have a negative effect on its future sales growth.
−Removed: The Company Expects to Face Increasing Competition From Other Providers of Diagnostic Tests, Sample Collection Products and Molecular Laboratory Services.
+Added: The Company Expects to Face Increasing Competition From Other Providers of Diagnostic Tests and Sample Collection Products.
The Company's rapid point-of-care tests compete with other point-of-care products made by the Company's competitors.
This competition is particularly evident with respect to the Company's OraQuick ADVANCE ® HIV-1/2 test and the Company's HIV Self-Test outside of the United States.
−Removed: The Oragene ® product line sold by the Company's subsidiary, DNAG, competes against other molecular sample management solutions, such as blood collection kits and buccal swabs and will likely face additional competition from collection devices similar in design and operation to the Company's Oragene ® and ORAcollect ® products.
−Removed: There are a number of products currently in or expected to enter the market for the
−Removed: detection of antigen to SARS-CoV-2 that currently or will compete with the Company's InteliSwab ® COVID-19 diagnostic test.
−Removed: The Company's genetic and microbiome laboratory services business is expected to face increasing competition, primarily from large commercial reference laboratories, hospital-based laboratories and specialty laboratories.
−Removed: The Company believes there is significant opportunity in the markets for these services, particularly the microbiome market which is still in the early stages.
−Removed: As these markets evolve and expand, the Company expects competition for genomic and microbiome laboratory services to intensify.
+Added: The Oragene ® product line sold by the Company's subsidiary, DNAG, competes against other sample management solutions, such as blood collection kits and buccal swabs and will likely face additional competition from collection devices similar in design and operation to the Company's Oragene ® and ORAcollect ® products.
+Added: Additionally, there are a number of products for the detection of antigen to SARS-CoV-2 that compete with the Company's InteliSwab ® COVID-19 diagnostic test.
There is significant competition, including from other companies and governmental organizations, who make and distribute rapid tests for COVID-19.
10 unchanged sentences
For example, in past years the Company's OraQuick ADVANCE ® HIV-1/2 test has been purchased through bulk procurement or other funding provided by governmental agencies.
−Removed: The Company's OraQuick ® HCV test has been purchased by customers who receive government funding, and the Company believes increased funding from the CDC and other agencies will be required to substantially increase the volume of HCV testing, especially in the public health market.
+Added: The Company's OraQuick ® HCV test has been purchased by customers who receive government funding, and the Company believes increased funding from government agencies will be required to substantially increase the volume of HCV testing, especially in the public health market.
There can be no assurance that purchases or funding from these agencies will occur or continue.
−Removed: As a result, the Company may expend considerable resources on unsuccessful sales efforts or it may not be able to complete transactions at all or on a schedule and in an amount consistent with its objectives.
+Added: In addition, government funding is subject to the political process, which is inherently fluid and unpredictable.
+Added: For example, the National Institutes of Health (“NIH”) announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect costs.
+Added: While, as of the date of this filing, the order has been temporarily stayed, there can be no assurance that it will not take effect or that other adverse actions will not be taken.
+Added: Further, our revenue may be adversely affected if our clients delay purchases as a result of uncertainties surrounding the approval of government budget proposals, including reduced allocations to government agencies.
+Added: In addition, government funding is subject to the political process, which is inherently fluid and unpredictable.
+Added: As a result, the Company may expend considerable resources on unsuccessful sales efforts or it
+Added: may not be able to complete transactions at all or on a schedule and in an amount consistent with its objectives or previous order patterns.
The Company's Inability To Expand International Sales Could Adversely Affect its Business and Results of Operations.
3 unchanged sentences
United Kingdom, Germany, France, Italy, Spain and Portugal.
−Removed: The Company is also working to expand international sales of its professional HIV and HCV products and its molecular sample management solutions.
−Removed: The Company also believes there is a significant opportunity for international sales of its InteliSwab ® COVID-19 Rapid Test once the necessary studies and registrations are complete.
+Added: The Company is also working to expand international sales of its professional HIV and HCV products and its sample management solutions.
While the Company believes international sales of these and other products represent attractive long-term opportunities with significant growth potential, there is no guarantee that these opportunities will materialize, continue or increase.
9 unchanged sentences
The Company seeks to increase revenue derived from international sales of its products.
−Removed: Its international sales accounted for $43.8 million, or 11% of consolidated revenues in 2023, $37.3 million, or 10% of consolidated net revenues in 2022, $45.3 million, or 19%, of consolidated net revenues in 2021.
+Added: Its international sales accounted for $13.9 million, or 7% of consolidated revenues in 2024, $14.6 million, or 4% of consolidated revenues in 2023, and $19.1 million, or 5% of consolidated net revenues in 2022.
In addition, the Company's subsidiary DNAG, which accounted for $52.5 million or 28% of consolidated net revenues in 2024, is operated in Canada.
8 unchanged sentences
• Regulatory requirements, including compliance with applicable customs regulations and the need to obtain or maintain regulatory approvals, registrations or reimbursement approvals for the Company's products;
−Removed: • Trade protection measures, additional trade sanctions and import/export licensing requirements;
+Added: • Trade protection measures, additional trade sanctions and import/export licensing requirements, and tariffs;
• The inability to obtain or maintain ISO certification for the Company's or the Company's suppliers’ manufacturing facilities;
9 unchanged sentences
• Economic conditions, inflation, political instability, the absence of available funding sources, terrorism, civil unrest, war and natural disasters in foreign countries;
−Removed: • Exposure to infectious disease and epidemics, including the effects of the COVID-19 outbreak on the Company's business operations in geographic locations impacted by the outbreak and on the business operations of the Company's customers and suppliers;
+Added: • Exposure to infectious disease and epidemics, including the effects of the COVID-19 outbreak on the Company's business operations and on the business operations of the Company's customers and suppliers;
• Long sales cycles in international markets, especially for sales to foreign governments, quasi-governmental agencies and international public health agencies;
4 unchanged sentences
• Reduced protection for, or enforcement of, the Company's patents and other intellectual property rights in foreign countries.
−Removed: In addition, the Company has contracted with a third party in Thailand for the manufacture of a portion of the Company's OraQuick ® HIV tests and all of DNAG’s products are produced in Canada.
+Added: In addition, the Company has contracted with a third party in Thailand for the manufacture of a portion of the Company's OraQuick ® HIV tests and certain DNAG products are produced in Canada.
The Company may enter into agreements to manufacture these or other products in additional foreign countries as well.
2 unchanged sentences
Foreign currency fluctuations and economic conditions in foreign countries could also increase the costs of manufacturing the Company's products in foreign countries.
−Removed: In addition, the COVID-19 pandemic previously resulted in, and may in the future result in, increased government-imposed travel restrictions and extended shutdowns of certain businesses in the affected locations as well as logistics delays due to the global logistical crisis from the pandemic.
−Removed: These or any further political or governmental responses to pandemic diseases could result in social, economic and labor instability of foreign countries, which could have a material adverse effect on the Company's business, results of operations and financial condition.
+Added: In addition, the COVID-19 pandemic resulted in, and potential future pandemics or other public health emergencies may in the future result in, increased government-imposed travel restrictions and extended shutdowns of certain businesses in the affected locations as well as logistics delays due to the global logistical crisis from such pandemic or other health emergency.
+Added: Future governmental responses to public health crises, including pandemics and epidemics could result in social, economic and labor instability of foreign countries, which could have a material adverse effect on the Company's business, results of operations and financial condition.
The Company's U.S.
3 unchanged sentences
Historically, the Company has sold a number of its products to the government under contracts with the General Services Administration and the Veterans Administration.
−Removed: In September 2022 the Company entered into an $8.6 million contract with BARDA to develop a second generation Ebola test on the OraQuick ® testing platform and the Company was selected to provide its OraQuick ® In-Home HIV tests in support of the CDC "Together Take me Home," HIV self-test program.
+Added: In September 2022, the Company entered into an $8.6 million contract with BARDA to develop a second generation Ebola test on the OraQuick ® testing platform, which was subsequently modified in September 2023 to add an additional $6.8 in funding to be used to obtain the appropriate regulatory approvals.
+Added: Also in September, 2022, the Company was selected to provide its OraQuick ® In-Home HIV tests in support of the CDC "Together Take me Home," HIV self-test program.
Under the program, the CDC is expected to provide $41.5 million over a five-year period to support community testing.
−Removed: During the third quarter of 2022, the Company entered into a contract with the DLA for the second procurement of the Company's InteliSwab ® COVID-19 Rapid Test for OTC use.
+Added: During the third quarter of 2022, the Company entered into a contract with the Defense Logistics Agency ("DLA") for the second procurement of the Company's InteliSwab ® COVID-19 Rapid Test for OTC use.
During the same quarter, the Company entered into a contract with the BARDA to provide it with up to $13.6 million in funding to obtain an FDA 510(k) clearance and CLIA waiver for the Company's InteliSwab® test.
7 unchanged sentences
government contracts.
−Removed: contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to the Company as compared to competitors that do not rely on government contracts.
+Added: government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to the Company as compared to competitors that do not rely on government contracts.
For example, the government has the right to terminate one or more of these contracts at its convenience even if the Company has not defaulted in any of its obligations.
11 unchanged sentences
Factors such as defective materials or processes, mechanical failures, human errors, environmental conditions, changes in materials or production methods, and other events or conditions could cause the Company's products or the materials used to produce or assemble its products to fail inspections and quality testing or otherwise not perform in accordance with their label claims or the expectations of the Company's customers.
−Removed: In February 2024, the FDA issued the Quality Management System Regulation (QMSR) Final Rule to amend the QSR, incorporating by reference the international standard for medical device quality management systems set by the International Organization for Standardization (ISO), ISO 13485:2016.
+Added: In February 2024, the FDA issued the Quality Management System Regulation (QMSR) Final Rule to amend the QSR, incorporating by reference the international standard for medical device quality management systems set by the
+Added: International Organization for Standardization (ISO), ISO 13485:2016.
The rule will become effective on February 2, 2026.
Until then, manufacturers are required to comply with the QSR.
−Removed: We believe that our facilities and procedures are in material compliance with the FDA’s OSR regulations, the European Union’s Quality Management Systems requirements, ISO 13485:2016, but the regulations are subject to change or may be unclear, and we cannot be sure that FDA investigators will agree with our compliance with the FDA’s post-market requirements.
+Added: We believe that our facilities and procedures are in material compliance with the FDA’s QSR requirements, the European Union’s Quality Management Systems requirements, ISO 13485:2016, but the regulations are subject to change or may be unclear, and we cannot be sure that FDA investigators will agree with our compliance with the FDA’s post-market requirements.
Any failure or delay in the Company's ability to meet the applicable specifications, performance standards, quality requirements or customer expectations could adversely affect its ability to manufacture and sell its products or comply with regulatory requirements.
4 unchanged sentences
As the Company increases its manufacturing capacity to meet market demand or begin to manufacture new products at scale, it may face unanticipated manufacturing challenges as production volumes increase, new processes are implemented and new supplies of raw materials used in these products are secured.
−Removed: In addition, the Company could experience delays in
−Removed: production as it increases manufacturing capacity or begins to manufacture new products that may result in its inability to meet product demand as the products ordered by its customers being on back-order as initial production issues are addressed.
+Added: In addition, the Company could experience delays in production as it increases manufacturing capacity or begins to manufacture new products that may result in its inability to meet product demand as the products ordered by its customers being on back-order as initial production issues are addressed.
If it experiences production delays or inefficiencies, a deterioration in the quality of the Company's products or other complications in managing changes to its manufacturing processes, including those that are designed to increase capacity, enhance efficiencies and reduce costs or that relate to new products or technologies, the Company may not achieve the benefits that it anticipates from these actions when expected, or at all, and the Company's operations could experience disruptions, the Company's manufacturing efficiency could suffer and the Company's business, financial condition and results of operations could be materially and adversely affected.
6 unchanged sentences
The availability and price of these materials, parts, products and services are affected by a variety of factors beyond the Company's control, including the willingness of suppliers to sell into the medical device industry, changes in supply and demand, general economic conditions, labor costs, fuel-related transportation costs, liability concerns, climate change (including new and existing laws and regulations to address climate change), competition, import duties, tariffs, currency exchange rates, inflationary pressures and political uncertainty around the world.
−Removed: The Company's suppliers often pass some of their cost increases on to it, and if such increased costs are sustained or increase further, its suppliers may pass further cost increases on to it.
+Added: Recently, the United States and certain other countries from which we import materials have imposed or signaled a willingness to impose tariffs on goods coming into the United States and elsewhere.
+Added: While we cannot be certain how this will impact our supply chain, the Company's suppliers often pass some of their cost increases on to it, and if such increased costs are sustained or increase further, its suppliers may pass further cost increases on to it.
In addition, transportation costs have generally increased and may further increase if crude oil prices increase.
The Company's transportation and service providers are typically able to pass any significant increases in oil prices on to it.
−Removed: The Company's costs may also be impacted by laws to increase minimum wages, including the potential increase to the federal minimum wage in the United States that has been recently proposed by the current administration.
+Added: The Company's costs may also be impacted by laws to increase minimum wages,
+Added: including the potential increase to the federal minimum wage in the United States that has been recently proposed by the current administration.
The Company's ability to recover such increased costs may depend upon its ability to raise prices on its products.
1 unchanged sentence
If the Company is unable to fully recover these costs through price increases or offset these increases through cost reductions, or it experiences terminations or interruption of its relationships with its suppliers, it could experience lower margins and profitability, and the Company's results of operations, financial condition and cash flows could be materially harmed.
−Removed: Recently, the global supply chain has experienced significant disruptions, resulting in shortages of labor and equipment.
+Added: In recent years, the global supply chain has experienced significant disruptions, resulting in shortages of labor and equipment.
These conditions, if not mitigated or remedied in a timely manner, could delay or preclude delivery of raw materials needed to manufacture the Company's products or delivery of the Company's products to customers, particularly in international markets.
3 unchanged sentences
For example, the biological antigens and antibodies, nitrocellulose and certain other components required to make the Company's OraQuick ® HIV, HCV and Ebola products are currently purchased from sole-source suppliers.
−Removed: The Company's OraSure QuickFlu ® test and the fully automated high-throughput drug assays sold with its Intercept i2 ® device are manufactured and supplied by sole-source suppliers and the conjugates used in its MICROPLATE oral fluid drugs-of-abuse assays are obtained from third-party suppliers.
−Removed: The Company has contracted with third parties in Thailand for parts of the assembly of OraQuick ® HIV device and the OraQuick ® HIV Self-Test in order to supply certain international
−Removed: In addition, the Company's subsidiary, DNAG, uses three third-party manufacturers to supply virtually all of its products, including its Oragene ® and ORAcollect ® lines of collection kits.
−Removed: Additionally, the Company's Intercept i2 ® he collection device is manufactured and supplied under a long-term agreement with Thermo Fisher, the sole-source supplier for these products.
−Removed: If Thermo Fisher were unable or unwilling to supply the necessary components for the manufacture of the Intercept i2 ® he collection devices, the Company would be unable to produce this product or offer it to customers.
+Added: The Company has contracted with third parties in Thailand for parts of the assembly of OraQuick ® HIV device and the OraQuick ® HIV Self-Test in order to supply certain international markets.
+Added: In addition, the Company's subsidiary, DNAG, uses third-party manufacturers to supply certain products, including its Colli-Pee ® , Oragene ® and ORAcollect ® lines of collection kits.
Any interruption in, or change in the cost or quality of, the supply of the necessary raw materials, manufacturing services, product and process development, or other materials necessary to manufacture the product could adversely impact the efficacy of the product and negatively affect the Company's reputation with its customers.
2 unchanged sentences
If the Company's sole-source suppliers were to otherwise cease supplying it, go out of business, or were unable to meet their obligations in a timely fashion or at an acceptable price, or at all, the Company may be forced to incur higher costs to obtain the necessary raw materials elsewhere, if it could even source such materials at all.
−Removed: Furthermore, the COVID-19 pandemic and the measures taken to contain the spread of the virus, have disrupted, and may in the future disrupt, the normal operations of the Company's third-party suppliers.
Additionally, potential future pandemics or other public health emergencies may, in the future, disrupt the normal operations of the Company's third-party suppliers.
−Removed: The Company's third-party suppliers may not have the personnel, raw materials, capacity or capability to manufacture its products according to its schedule and specifications.
+Added: Furthermore, the Company's third-party suppliers may not have the personnel, raw materials, capacity or capability to manufacture its products according to its schedule and specifications.
To the extent any such production and distribution interruption or closures occur and continue for an extended period of time, the impact on the Company's supply chain could have a material adverse effect on its results of operations.
18 unchanged sentences
In addition, government-funded inventions must be reported to the government, government funding must be disclosed in any resulting patent applications, and the Company's rights in such inventions may be subject to certain requirements to manufacture products in the United States.
−Removed: On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights that would be voluntary for federal government agencies to follow when deciding whether to exercise march-in rights and which for the first time includes the price of a product as a factor a federal government agency can use when deciding to exercise march-in rights.
+Added: In late 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights that would be voluntary for federal government agencies to follow when deciding whether to exercise march-in rights and which for the first time includes the price of a product as a factor a federal government agency can use when deciding to exercise march-in rights.
While march-in rights have not previously been exercised, it is uncertain whether the federal government will actually exercise such march-in rights in connection with medical products or whether any such exercise will be subject to judicial review or challenge.
23 unchanged sentences
Regulatory approval or clearance must be obtained before most products may be sold and additional development efforts on these products may be required before any regulatory authority will review them.
−Removed: Similarly, regulatory clearances or registrations, such as a CLIA certification, and compliance with industry guidelines, may be required in order to provide competitive laboratory services.
As noted above, regulatory authorities may not issue such approvals, clearances or certifications or may substantially delay or condition such action.
−Removed: Even if a product or service is developed and all applicable regulatory approvals, clearance or certifications are obtained, there may be little or no market for the product or service and entry into or development of new markets for the Company's products and services may require an investment of substantial resources, such as new employees, offices and manufacturing facilities.
+Added: Even if a product is developed and all applicable regulatory approvals, clearance or certifications are obtained, there may be little or no market for the product and entry into or development of new markets for the Company's products and services may require an investment of substantial resources, such as new employees, offices and manufacturing facilities.
Moreover, the Company may spend a significant amount of money on manufacturing facilities, advertising or other activities and fail to develop a market for the product or service.
−Removed: Other factors that could affect the success of the Company's efforts include its ability to manufacture products or provide laboratory services in a cost-effective manner and whether it can obtain necessary intellectual property rights and protection in the markets where the product or service is sold.
+Added: Other factors that could affect the success of the Company's efforts include its ability to manufacture products in a cost-effective manner and whether it can obtain necessary intellectual property rights and protection in the markets where the product or service is sold.
If the Company fails to develop and gain commercial acceptance for its products and services, or if competitors develop more effective products and services or a greater number of successful new products and services, customers may decide not to purchase the Company's products and services or may purchase and use products and services developed by its competitors.
4 unchanged sentences
To the extent that such a large customers fail to meet their purchase commitments, change their ordering patterns or business strategies, or otherwise reduce their purchases or stop purchasing the Company's products, or if it experiences difficulty in meeting the high demand by these larger customers for its products, the Company's revenues and results of operations could be adversely affected.
+Added: The Company is Subject to Risks Related to Government Funding and Customer Ordering.
+Added: A portion of our revenues is derived from sales to customers that rely on funding from the U.S.
+Added: government, including federal agencies, state programs, and entities receiving grants and contracts from the HHS, the U.S.
+Added: Agency for International Development (“USAID”), the Centers for Disease Control and Prevention (“CDC”), and other government programs.
+Added: Any reduction, delay, or uncertainty in the availability of such funding could adversely affect the purchasing patterns of these customers, impacting our business, financial condition, and results of operations.
+Added: In recent months, the U.S.
+Added: government has implemented funding freezes and delays that have directly affected healthcare and life sciences procurement.
+Added: For example, on January 22, 2025, the Office of Management and Budget (“OMB”) issued a directive halting the disbursement of certain federal funds, pending review of budgetary priorities.
+Added: Similarly, on February 10, 2025, the U.S.
+Added: Department of State and USAID announced a 90-day suspension of new foreign assistance obligations, affecting global health initiatives and domestic procurement of essential healthcare supplies.
+Added: Customers that rely on these funding sources may reduce, delay, or cancel orders for our products and services, particularly during periods of political uncertainty.
+Added: If our customers experience prolonged funding uncertainty or reductions in available government funds, we could face disruptions in our revenue streams, increased inventory costs due to unpredictable ordering patterns, and potential declines in profitability.
+Added: While we actively monitor legislative and regulatory developments, we cannot predict the outcome of government policy shifts that may impact our customers’ ability to procure our products.
Acquisitions or Investments May Not Generate the Expected Benefits and Could Disrupt the Company's Ongoing Business, Distract Its Management, Increase Its Expenses and Adversely Affect Its Business.
1 unchanged sentence
For example, in January 2024, the Company announced its investment and entry into wide ranging strategic distribution agreements with KKR Sapphiros L.P.
−Removed: ("Sapphiors").
+Added: ("Sapphiros"), and in December 2024, the Company acquired Sherlock Biosciences, Inc.
+Added: ("Sherlock"), expanding the Company's product pipeline with the addition of
+Added: Sherlock's molecular diagnostics platform.
The Company will likely continue to pursue strategic acquisitions or investments as a way to expand its business.
19 unchanged sentences
• An acquisition may result in the loss of the Company's or the acquired company’s key personnel, customers, distributors or suppliers;
−Removed: • An acquisition of a foreign business may involve additional risks, including, but not limited to, foreign currency exposure, liability or restrictions under foreign laws or regulations, and the Company's inability to successfully assimilate differences in foreign business practices or overcome language or cultural barriers and other inherent risks of operating in unfamiliar legal and regulatory environments.
+Added: • An acquisition of a foreign business may involve additional risks, including, but not limited to, foreign currency exposure, liability or restrictions under foreign laws or regulations, and
+Added: the Company's inability to successfully assimilate differences in foreign business practices or overcome language or cultural barriers and other inherent risks of operating in unfamiliar legal and regulatory environments.
The occurrence of one or more of the above or other factors may prevent the Company from achieving all or a significant part of the benefits expected from an acquisition or investment.
This may adversely affect the Company's financial condition, results of operations and ability to grow its business or otherwise achieve its financial and strategic objectives.
+Added: We May Fail to Realize the Anticipated Benefits of the Acquisition of Sherlock.
+Added: The success of the acquisition of Sherlock will depend on, among other things, our ability to combine our business with Sherlock in a manner that allows us to achieve developmental and operational synergies.
+Added: The integration process could result in the loss of key employees, the disruption of our ongoing business or the ongoing business of Sherlock, or inconsistencies in standards, controls, procedures, or policies, in each case, that could adversely affect our ability to achieve the anticipated benefits of the acquisition.
+Added: Integration efforts between the two companies will also divert management's attention from our core business and other opportunities that could have been beneficial to our stockholders.
+Added: An inability to realize the full extent of, or any of, the anticipated benefits of the acquisition, as well as any delays encountered in the integration process, could have an adverse effect on our business and results of operations, which may affect the value of our common stock.
+Added: If we are unable to achieve these objectives, the anticipated benefits of the acquisition may not be realized fully or at all or may take longer or cost more to realize than expected.
The Company's Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints.
28 unchanged sentences
In international markets, the Company often sell products such as its OraQuick ® HIV Self-Test to or through foreign governmental agencies or parties funded by such agencies.
−Removed: Many of the Company's molecular sample management solutions are sold to researchers at academic institutions, pharmaceutical and biotechnology companies, government laboratories and private foundations.
+Added: Many of the Company's sample management solutions are sold to researchers at academic institutions, pharmaceutical and biotechnology companies, government laboratories and private foundations.
Many research customers are dependent for their funding on grants from U.S.
−Removed: governmental agencies such as the U.S.
−Removed: National Institutes of Health and agencies in other countries to pay for the products and services they purchase.
−Removed: These research customers also purchase the Company's genomic and microbiome laboratory tests and analytical services.
+Added: governmental agencies such as the NIH and agencies in other countries to pay for the products and services they purchase.
+Added: These research customers also purchase the Company's single order fulfillment services.
+Added: Government funding is subject to the political process, which is inherently fluid and unpredictable.
+Added: Under the Trump administration, the NIH announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect costs.
+Added: Indirect costs represented more than 25% of total grant dollars awarded by the NIH in 2023.
+Added: Our research customers may face increased financial pressure due to this change or any future caps on indirect costs.
+Added: While, as of the date of this filing, the order has been temporarily stayed, there can be no assurance that it will not take effect or that other adverse actions will not be taken.
+Added: Further, our revenue may be adversely affected if our research customers delay purchases as a result of uncertainties surrounding the approval of government budget proposals, including reduced allocations to government agencies, such as the NIH.
+Added: The Company has also received government funding for certain research and development projects, including, most recently, through the Rapid Response Partnership Vehicle ("RRVP") for the development of a Marburg Virus Disease ("MVD") rapid antigen test.
The level of available government grants or funding in the U.S.
55 unchanged sentences
The Company's trade secrets could become known through other unforeseen means.
−Removed: Although the Company has licensed certain technology for use in its microbiome laboratory services offerings and it has developed proprietary know-how that it uses in this business, it does not currently hold any patents covering the laboratory processes and analytical methods offered to its customers.
−Removed: The absence of patent protection in this or other parts of the Company's business may make it more difficult to protect its intellectual property.
+Added: The absence of patent protection in certain parts of the Company's business may make it more difficult to protect its intellectual property.
In addition, the Company's competitors may independently develop similar or alternative technologies or products that are equal or superior to its technology.
13 unchanged sentences
The Company May Become Involved in Intellectual Property Disputes, Which Could Increase Its Costs and Limit or Eliminate Its Ability to Sell Products, Provide Services or Use Certain Technologies.
−Removed: From time to time, the Company may seek to enforce its patents or other intellectual property rights through litigation.
+Added: From time to time, the Company has sought, and may in the future seek, to enforce its patents or other intellectual property rights through litigation.
In addition, there are a large number of patents and patent applications in the Company's product and service areas, and additional patents may be issued to third parties relating to its product and service areas.
22 unchanged sentences
Opposition or revocation proceedings could be instituted in a foreign patent office as well.
−Removed: Under federal law, various forms of post issuance patent review proceedings have been authorized, including an inter-parties review process.
+Added: Under federal law, various forms of post issuance patent review proceedings have been authorized, including inter-parties review processes.
These proceedings permit certain persons to challenge the validity of a patent on the grounds that it was known from the prior art.
+Added: As a result of such proceedings several of the Company's patents have been successfully challenged.
The filing of such proceedings, or the issuance of an adverse decision in such proceedings, could result in the loss of valuable patent rights that could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects.
4 unchanged sentences
Many of the Company's proposed and existing products and services are subject to regulation by the FDA and other governmental or public health agencies.
−Removed: In particular, the Company is subject to strict governmental controls on the development, manufacture, labeling, distribution and marketing of its products and the processes and procedure for its laboratory services.
+Added: In particular, the Company is subject to strict governmental controls on the development, manufacture, labeling, distribution and marketing of its products.
The Company's practice is to train its employees on the legal requirements applicable to its business, including the requirements of the FDA and other relevant agencies.
7 unchanged sentences
All in vitro diagnostic products that are to be sold in the EU must bear the CE mark indicating conformance with the requirements of the relevant EU in vitro diagnostic medical devices legislation.
−Removed: The new EU Regulation 2017/746 on in vitro diagnostic medical devices ("IVDR"), became applicable on May 26, 2022 and repealed the previous Directive 98/79/EC, ("IVDD").
−Removed: There is a transitional period during which products that have a declaration of conformity issued under the IVDD prior to May 26, 2022 may continue to be placed on the EU market for a certain period before requiring certification under the IVDR (subject to compliance with certain requirements under the IVDR, including in respect of post-market surveillance);
−Removed: however, class A non-sterile products do not benefit from such transitional provisions and have been required to be IVDR compliant since May 26, 2022, while Class D devices benefit from such transitional provisions until May 26, 2025.
−Removed: On January 23, 2024, the European Commission introduced a legislative proposal to extend such transitional provisions for certain devices.
−Removed: The European Commission has provided the legislative proposal to the European Parliament and the European Council for their review and approval.
−Removed: Once the European Commission’s legislative proposal is approved (with or without amendment), it will be adopted into EU law.
+Added: The EU IVDR became applicable on May 26, 2022 and repealed the previous IVDD.
+Added: There is a transitional period during which products that have a declaration of conformity issued under the IVDD prior to May 26, 2022 may continue to be placed on the EU market for a certain period before requiring certification under the EU IVDR, subject to compliance with certain requirements under the EU IVDR (see the section titled "Governmental Regulation - International" for further Information).
The Company has obtained the CE mark for several of its existing products under the IVDD.
−Removed: It also intends to apply for CE marks for certain of its future products and is not aware of any material reason why it would be unable to obtain those marks.
−Removed: However, there can be no assurance that compliance with all provisions of the IVDR will be demonstrated and the CE mark will be obtained or maintained for all products that the Company desires to sell in the EU.
−Removed: The failure to obtain or maintain the CE mark for one or more of the
−Removed: Company's products could lead to the termination of strategic alliances and agreements for sales of those products in the EU and mean that the Company is unable to sell such products in the EU.
+Added: It also intends to apply for CE marks for certain of its future
+Added: products and is not aware of any material reason why it would be unable to obtain those marks.
+Added: However, there can be no assurance that compliance with all provisions of the EU IVDR will be demonstrated and the CE mark will be obtained or maintained for all products that the Company desires to sell in the EU.
+Added: The failure to obtain or maintain the CE mark for one or more of the Company's products could lead to the termination of strategic alliances and agreements for sales of those products in the EU and mean that the Company is unable to sell such products in the EU.
In addition, the Company or its distributors are often required to obtain premarket authorization or product registration with foreign governments or regulatory bodies before it can import and sell its products in foreign countries.
19 unchanged sentences
The Company's Inability to Respond to Changes in Regulatory Requirements Could Adversely Affect Its Business.
−Removed: The Company believes that its products and procedures are in material compliance with all applicable FDA regulations, ISO requirements, and other applicable regulatory requirements, but the regulations regarding the manufacture and sale of its products, the QSR and ISO requirements, and other requirements may be unclear and are subject to change.
+Added: The Company believes that its products and procedures are in material compliance with all applicable FDA regulations, ISO requirements, and other applicable regulatory requirements, but the regulations regarding the manufacture and sale of
+Added: its products, the QSR and ISO requirements, and other requirements may be unclear and are subject to change.
Newly promulgated regulations could require changes to the Company's products, necessitate additional clinical trials or procedures, or make it impractical or impossible for it to market its products for certain uses, in certain markets, or at all.
2 unchanged sentences
The implementation of such changes or new or additional requirements may result in additional clinical trials and substantial additional costs and could delay or make it more difficult or complicated to obtain approvals and sell the Company's products.
+Added: In addition, from time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA.
+Added: In addition to new legislation, FDA regulations, guidance and policies are often revised or reinterpreted by the FDA in ways that may significantly affect the manner in which our products are regulated and marketed.
The Company cannot predict the effect, if any, that these changes might have on its business, financial condition or results of operations.
23 unchanged sentences
The Company is subject to European data protection regulations where it collects and uses personal data related to Europe.
−Removed: This includes the EU General Data Protection Regulation (“GDPR”) as well as other national data protection legislation in force in relevant European Economic Area (“EEA”) member states, which govern the collection, use, storage, disclosure, transfer, or other processing of personal data:
+Added: This includes the EU General Data Protection Regulation (“EU GDPR”) as well as other national data protection legislation in force in relevant European Economic Area (“EEA”) member states, and the EU GDPR in such form as incorporated into the laws of the UK ("UK GDPR", together with EU GDPR, "GDPR"), which govern the collection, use, storage, disclosure, transfer, or other processing of personal data:
(i) regarding individuals in the EEA;
and/or (ii) carried out in the context of the activities of the Company's establishment in any EEA member state.
−Removed: Failure to comply with the GDPR, and any supplemental European Economic Area (“EEA”) country’s national data protection laws which may apply by virtue of the location of the individuals whose personal data the Company collects, may result in fines and other administrative
−Removed: penalties, including fines of up to the greater of 4% of worldwide turnover and €20 million.
+Added: Failure to comply with the GDPR, and any supplemental European Economic Area (“EEA”) country’s national data protection laws which may apply by virtue of the location of the individuals whose personal data the Company collects, may result in fines and other administrative penalties, including fines of up to the greater of 4% of worldwide turnover and €20 million (or £17.5 million in the UK).
The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.
−Removed: The GDPR imposes several mandatory requirements on companies that process personal data, including requirements relating to the processing of health and other sensitive data, legal basis for processing personal data which may include obtaining the consent of the individuals to whom the personal data relates, providing notice to individuals about personal data processing activities, having data processing agreements with third parties who process personal data, notification of personal data breaches to data protection authorities and individuals, and the implementing of safeguards to protect the security and confidentiality of the personal data.
−Removed: The GDPR also imposes strict rules on the transfer of personal data out of the EEA to third countries, including the United States in certain circumstances, unless a derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses, or SCCs) have been put in place and a transfer impact assessment carried out.
+Added: The GDPR imposes several mandatory requirements on companies that process personal data, including requirements relating to the processing of special category personal data (such as health sensitive data), ensuring a legal basis or condition applies to the processing of personal data, which may include obtaining the consent of the individuals to whom the personal data relates, providing notice to individuals about personal data processing activities, having data processing agreements with third parties who process personal data, notification of personal data breaches to data protection authorities and individuals, and the implementing of safeguards to protect the security and confidentiality of the personal data.
+Added: The GDPR also imposes strict rules on the transfer of personal data out of the EEA to third countries, including the United States in certain circumstances, unless a derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses, or SCCs, or the EU-US Data Privacy Framework) applies.
Any inability to transfer personal data from the EEA to the United States in compliance with data protection laws may impede the Company's ability to conduct trials and may adversely affect its business and financial position.
1 unchanged sentence
Further, the Company has no assurances that violations will not occur, particularly given the complexity of the GDPR.
−Removed: The Company is also subject to the California Consumer Privacy Act of 2018 (“CCPA”), which took effect on January 1, 2020.
−Removed: The CCPA imposes extensive new requirements and protections on the processing of personal data, aimed at giving California consumers more visibility and control over their personal information.
+Added: In the U.S., there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including health information privacy laws, security breach notification laws and consumer protection laws.
+Added: Each of these laws is subject to varying interpretations and is constantly evolving.
+Added: By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon “covered entities” (health plans, health care clearinghouses and certain health care providers), and their respective business associates (individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity).
+Added: Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations.
+Added: Even when HIPAA does not apply, failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (the FTCA), 15 U.S.C § 45(a).
+Added: The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities.
+Added: Individually identifiable health information is considered sensitive data that merits stronger safeguards.
+Added: Regulators and legislators in the U.S.
+Added: are increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries.
+Added: For example, the Biden Administration’s executive order Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern as implemented by Department of Justice regulations issued in December 2024, prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China.
+Added: The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls.
+Added: Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions, and may result in exclusion from participation in federal and state programs.
+Added: The Company is also subject to the California Consumer Privacy Act (“CCPA”), which creates individual privacy rights and places stringent privacy and security obligations on businesses covered by the law, including obligations to provide detailed disclosures to California consumers about their data collection, use and sharing practices and provide such
+Added: consumers with ways to opt out of certain uses of sensitive personal information, including health information.
+Added: It also provides for civil penalties for violations and allows for a private right of action for data breaches that is expected to increase data breach litigation.
+Added: The law also created a new state regulatory agency that was vested with authority to implement and enforce the CCPA.
Failure to comply with the CCPA or other data processing or security laws, or any changes in these laws, could adversely impact the Company's business and its business plans.
−Removed: In 2020, California residents voted the California Privacy Rights Act (the "CPRA") into law.
−Removed: The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data.
−Removed: The CPRA also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement.
−Removed: The majority of the CPRA provisions became effective on January 1, 2023, and additional compliance investment and potential business process changes may be required.
−Removed: Similar laws have been proposed, and likely will be proposed, in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.
+Added: Similar laws have been passed and proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.In addition to these comprehensive consumer privacy laws and proposals, a number of other states have passed or proposed more limited privacy laws that focus on specific privacy issues such as biometric data and the privacy of health and medical information, such as Washington state’s My Health My Data Act, which went into effect in March 2024.
+Added: In addition to privacy and data security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future.
+Added: We are also bound by other contractual obligations related to privacy and data security, and our efforts to comply with such obligations may not be successful.
+Added: We publish privacy policies, and we may publish marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data security.
+Added: If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.
+Added: We are subject to laws and regulations that govern sending marketing and advertising by electronic means, such as email and telephone.
+Added: For example, in the United States, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (the “CAN-SPAM Act”), among other things, obligates the sender of commercial emails to provide recipients with the ability to opt out of receiving future commercial emails from the sender.
+Added: In addition, the Telephone Consumer Protection Act (the “TCPA”) imposes certain notice, consent, and opt-out obligations on companies that send telephone or text communications using automatic telephone dialing systems, or artificial or prerecorded voice to consumers, and provides consumers with private rights of action for violations.
+Added: The FCC and the FTC have responsibility for regulating various aspects of these laws.
+Added: Among other requirements, the TCPA requires us to obtain prior express written consent for certain telemarketing calls.
+Added: Many states have similar consumer protection laws regulating telemarketing.
+Added: These laws limit our ability to communicate with potential customers and reduce the effectiveness of our marketing programs.
+Added: For violations of the TCPA, the law provides for a private right of action under which a plaintiff may recover monetary damages of $500 for each call or text made in violation of the prohibitions on calls made using an “artificial or pre-recorded voice” or an automatic telephone dialing system.
+Added: Various state law equivalents of the TCPA may also provide for monetary damages in amounts greater than those provided for under the TCPA.
+Added: An action may be brought by the FCC, a state attorney general, an individual, or a class of individuals.
+Added: If in the future we are found to have violated the TCPA, or a state law equivalent, the amount of damages and potential liability could be extensive and adversely impact our business.
+Added: Accordingly, were such a class certified or if we are unable to successfully defend such a suit, then TCPA or other state law damages could have a material adverse effect on our results of operations and financial condition.
+Added: The Use of New And Evolving Technologies, Such As Artificial Intelligence (“AI”), In Our Offerings May Present Risks And Challenges That Can Impact Our Business Including by Posing Security Risks to Our Confidential Information, Proprietary Information, and Personal Data.
+Added: We may build and integrate AI into our business practices, and the evolving nature of AI technologies and the surrounding legal and regulatory environment presents risks and uncertainties that could affect our business.
+Added: The use of AI technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement.
+Added: Additionally, we expect to see increasing government regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area.
+Added: For example, in the U.S., a number of states have proposed and passed laws regulating various uses of AI.
+Added: In Europe, the EU’s Artificial Intelligence Act (“AI Act”) — which entered into force on August 1, 2024 and, with some exceptions, will begin to apply as of August 2, 2026 — imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems.
+Added: If we develop or deploy AI systems that are governed by these laws and regulations, we may be required to adopt higher standards of data quality, transparency, and human oversight, and adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements.
+Added: Even in the absence of dedicate AI laws and regulations, we may be subject to novel legal and business risks relating to our adoption of these new technologies.
+Added: Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with
+Added: respect to privacy and data security.
+Added: Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property.
+Added: Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.
FDA Regulation of Laboratory-Developed Tests and Genetic Testing Could Affect Demand For the Company's Products.
7 unchanged sentences
The discussion paper has no legal status and does not represent a final version of the LDT draft guidance documents.
−Removed: The Company cannot predict what policies will be adopted with respect to regulating LDTs.
−Removed: The FDA has been working with regulatory advocacy groups to bring forward legislative approaches specifically for in vitro diagnostic tests including LDTs.
+Added: The FDA worked with regulatory advocacy groups to bring forward legislative approaches specifically for in vitro diagnostic tests including LDTs.
For example, in 2021, the Verifying Accurate, Leading-edge, IVCT Development ("VALID") Act was introduced to Congress and provided a framework to change IVDs and LDTs to in vitro clinical tests ("IVCTs").
2 unchanged sentences
Subsequently, the VALID Act was introduced to Congress again in March 2023.
−Removed: On October 3, 2023, the FDA published a proposed rule on LDTs, in which the FDA proposes to end enforcement discretion for virtually all LDTs in five stages over a four-year period from the date the FDA publishes a final rule.
−Removed: In Phase 1 (effective one year post-finalization), laboratories would be required to comply with medical device (adverse event) reporting and correction/removal reporting requirements.
−Removed: In Phase 2 (effective two years post-finalization),
−Removed: laboratories would be required to comply with all other device requirements (e.g., registration/listing, labeling, investigational use), except for quality systems and premarket review.
−Removed: In Phase 3 (effective three years post-finalization), laboratories would be required to comply with quality systems requirements.
−Removed: In Phase 4 (effective three and a half years post-finalization, but not before October 1, 2027), laboratories would be required to comply with premarket review requirements for high-risk tests (i.e., tests subject to the PMA requirement).
−Removed: Finally, in Phase 5 (effective four years post-finalization, but not before April 1, 2028), laboratories would be required to comply with premarket review requirements for moderate- and low-risk tests (i.e., tests subject to De Novo or the 510(k) requirement).
−Removed: Unlike previous proposals, the proposed rule does not include provisions that would allow for “grandfathering” of existing tests.
−Removed: The content and timing of any final rule on LDTs is uncertain at this time.
+Added: On April 29, 2024, the FDA published a final rule on LDTs, in which FDA outlines its plan to end enforcement discretion for many LDTs in five stages over a four-year period.
+Added: • In Phase 1 (effective May 6, 2025), clinical laboratories would be required to comply with medical device reporting, correction/removal reporting, and certain quality systems complaint handling requirements.
+Added: • In Phase 2 (effective May 6, 2026), clinical laboratories would be required to comply with all other device requirements (e.g., establishment registration and device listing, labeling, investigational use requirements), except for remaining quality systems requirements and premarket review requirements.
+Added: • In Phase 3 (effective May 6, 2027), clinical laboratories would be required to comply with all remaining quality systems requirements.
+Added: • In Phase 4 (effective November 6, 2027), clinical laboratories would be required to comply with premarket submission requirements for high-risk tests (i.e., tests subject to FDA's premarket approval (PMA) requirement).
+Added: • In Phase 5 (effective May 6, 2028), clinical laboratories would be required to comply with premarket submission requirements for moderate- and low- risk tests (i.e., tests subject to de novo classification or the 510(k) requirement).
+Added: On May 29, 2024, the American Clinical Laboratory Association filed a lawsuit challenging the FDA's authority to regulate LDTs as medical devices under the FDCA.
+Added: Subsequently, on August 19, 2024, the Association for Molecular Pathology filed a lawsuit similarly challenging FDA's final rule on LDTs.
+Added: The outcomes of these lawsuits is uncertain at this time.
The Company's subsidiary, DNAG, sells its DNA collection systems to certain laboratories and other customers for use with LDTs.
4 unchanged sentences
As a result of these activities, the FDA has issued letters to genetic testing laboratories indicating that it plans to increase oversight of this market which has caused some of these companies to stop providing testing options or to change how they are reporting the information provided by the testing.
−Removed: The activities have negatively affected this market and there is a risk that these enforcement actions will continue to negatively affect this market by forcing laboratories to either stop offering such services or restricting the use of such services.
+Added: The activities have negatively affected this market and there is a risk that these enforcement actions will continue to negatively affect this market by forcing
+Added: laboratories to either stop offering such services or restricting the use of such services.
Such a reduction in testing could result in decreased sales of the Company's DNA collection devices.
10 unchanged sentences
Violations of the FCPA and other laws may result in criminal or civil sanctions, which could be severe and the Company may be subject to other liabilities, which could negatively affect its reputation, business, results of operations and financial condition.
−Removed: Risks Relating to the Economy, the Company's Financial Results, Investments, Credit Facilities and Need for Financing
+Added: Risks Relating to the Economy, the Company's Financial Results, Investments, and Need for Financing
The Company Has Experienced Losses in the Past and May Not Be Able to Again Achieve and Maintain Profitable Operations .
−Removed: The Company has experienced annual net losses during the five years prior to 2015 and between 2020 through 2022.
+Added: The Company has experienced annual net losses during the five years prior to 2015, between 2020 through 2022 and again recorded net losses for the year ended December 31, 2024 .
In addition, as of December 31, 2024, the Company had an accumulated deficit of $103.4 million.
1 unchanged sentence
The Company's ability to achieve and continue profitable operations in the future will be dependent upon a number of factors including, without limitation, the following:
−Removed: • The Company's ability to continue growing sales of its molecular sample management solutions and related genomic and microbiome laboratory services;
−Removed: • The Company's ability to produce and successfully commercialize its InteliSwab® COVID-19 Rapid Tests and compete with comparable products;
−Removed: • The Company's ability to grow its OraQuick ADVANCE ® HIV 1/2 test in the United States and expand sales of its OraQuick® HIV Self-Test internationally;
−Removed: • Changes in the markets in which the Company operates, including changes in the prevalence of COVID-19;
+Added: • The Company's ability to continue growing sales of its sample management solutions and related genomic and microbiome laboratory services;
+Added: • The Company's ability to successfully commercialize its products in the United States and internationally;
+Added: • Changes in the markets in which the Company operates;
• Changes in customer buying patterns or a buildup of significant quantities in the Company's distributors’ inventories or distribution channels;
1 unchanged sentence
• The Company's ability to expand its business through the acquisition of other companies or technologies or through internal development of new or improved products;
−Removed: • The Company's ability to realize revenues and other anticipated benefits from its distribution relationship with Sapphiros;
+Added: • The Company's ability to realize revenues and other anticipated benefits from its acquisitions and strategic transactions;
• The Company's ability to improve manufacturing efficiencies and reduce cost of goods sold;
3 unchanged sentences
• The level of competition, including the degree to which competitors sell lower priced products or more attractive offerings to compete with the Company's products;
−Removed: • Changes in economic conditions in domestic or international markets, such as economic downturns, reduced demand, inflation and currency fluctuations;
+Added: • Changes in economic conditions in domestic or international markets, such as economic downturns, reduced demand, inflation, currency fluctuations and tariffs;
• Global economic and political instability and conflicts, such as terrorism, civil unrest, war and natural disasters in foreign countries;
13 unchanged sentences
If the Company is unable to obtain adequate financing or financing on terms satisfactory to it, the Company could face significant limitations on its ability to invest in its operations and otherwise suffer harm to its business.
−Removed: Economic Volatility and Disruption, Including Those Related to the COVID-19 Pandemic, Could Adversely Affect the Company's Business, Financial Performance, Results of Operations, Cash Flow and Financial Condition or Those of Its Customers and Suppliers .
−Removed: Global and U.S.
−Removed: markets and economies have experienced extreme volatility and disruption following the global outbreak of COVID-19 that has continued throughout 2023.
−Removed: Volatile economic conditions may occur again or continue in the future.
−Removed: Impacts of the COVID-19 pandemic that the Company has or may experience in the future include, but are not limited to:
−Removed: • a slowdown or stoppage in the supply chain of the raw materials and components used to manufacture its products;
−Removed: • interruptions or delays in domestic and/or international shipment of its products to its distributors and customers;
−Removed: • interruptions in normal operations of certain end-use customers that could result in reductions in demand for its products;
−Removed: • disruptions to the Company's operations, including a shutdown of its facilities or product lines;
−Removed: restrictions on its operations and sales, marketing and distribution efforts;
−Removed: and interruptions to its research and development, manufacturing, clinical/regulatory and other important business activities;
−Removed: • shutdown or interruption of the Company's manufacturing facilities due to contamination and costs incurred to clean and disinfect a facility following contamination;
−Removed: • inefficiencies and increased costs in the Company's production and shipping processes due to premium pay for manufacturing and certain other employees as well as social distancing and personal protective equipment requirements;
−Removed: • limitations on employee resources and availability, including due to sickness, government restrictions, the desire of employees to avoid contact with large groups of people or mass transit disruptions;
−Removed: • a fluctuation in foreign currency exchange rates or interest rates could result from market uncertainties;
−Removed: • an increase in exposure to credit losses for customers adversely affected by the COVID-19 pandemic;
−Removed: • an increase in regulatory restrictions or continued market volatility could hinder the Company's ability to execute strategic business activities, including acquisitions.
−Removed: These conditions could adversely affect the Company's financial performance and condition or those of its customers and suppliers.
−Removed: These circumstances could also adversely affect the Company's access to liquidity needed to conduct or expand its business or conduct future acquisitions or make other discretionary investments.
−Removed: Many of the Company's customers rely on public funding provided by federal, state and local governments, and this funding has been and may continue to be reduced or deferred as a result of economic conditions or other factors.
−Removed: These circumstances may adversely impact the Company's customers and suppliers, which, in turn, could adversely affect their ability to purchase and/or distribute the Company's products or supply it with necessary equipment, raw materials or components.
−Removed: Any or all of these effects would have an adverse effect on the Company's operations, business, financial condition and results of operations.
−Removed: Although there are positive signs that COVID-19 has begun to subside as compared to the height of the pandemic, the duration of the COVID-19 pandemic is still unknown, and it is difficult to predict the full extent of potential impacts the pandemic will have in the future on the Company's business, operations, and financial results, or on its customers, suppliers or logistics providers, or on the global economy as a whole.
−Removed: It is uncertain how materially the COVID-19 pandemic will affect the Company's global operations, particularly if the effects continue or get worse over an extended period of time.
−Removed: Even with the improvement of economic conditions, it may take time for the Company's customers and suppliers to establish new budgets and return to normal purchasing and shipping patterns.
−Removed: The Company cannot predict the re-occurrence of any economic slowdown or the strength or sustainability of an economic recovery.
Rising Inflation Rates Could Negatively Impact the Company's Revenues and Profitability if Increases in the Prices of Its Products or a Decrease in Consumer Spending Results in Lower Sales.
In Addition, if the Company's Costs Increase and the Company Is Not Able to Pass Along These Price Increases to Its Customers, Its Net Income Would Be Adversely Affected, and the Adverse Impact May Be Material.
−Removed: Inflation rates, particularly in the United States, have increased recently to levels not seen in years.
+Added: Inflation rates, particularly in the United States, increased in recent years and continue to be subject to volatility.
Increased inflation may result in decreased demand for the Company's products and services, increased operating costs (including the Company's labor costs), reduced liquidity, and limitations on its ability to access credit or otherwise raise debt and equity capital.
4 unchanged sentences
A reduction in the Company's revenue would be detrimental to its profitability and financial condition and could also have an adverse impact on its future growth.
+Added: Increasing Geopolitical and Economic Risk and Tariffs Could Negatively Affect Our Ability to Maintain Sales at Existing Levels
+Added: The imposition of tariffs, non-tariff barriers, and other import and export restrictions have contributed to increased global economic uncertainty.
+Added: The rise of economic nationalism could make it more difficult for us to attract new customers, retain existing customers, continue to produce and source in an optimal manner, maintain our supply chain, or maintain sales at existing levels, both in the United States and in other countries.
+Added: Geopolitical and economic risks, together with trade protectionism have increased over the past few years in many regions of the world, including in the United States.
+Added: Any of these risks, ensuing retaliation, or the further deterioration of trade relations between countries could make our offerings more expensive or non-competitive in the affected countries.
+Added: Growing tensions, protectionist trade policies, and tariffs may also lead to a fragmentation of the global economy, a general reduction of international trade in goods and services, and a reduction in the integration of financial markets, any of which could materially and adversely affect our business results, cash flows, financial condition, or prospects.
An Impairment of Goodwill and Intangible Assets Could Reduce the Company's Earnings .
30 unchanged sentences
The following factors, among others, could have a significant impact on the market for the Company's Common Stock:
−Removed: • The performance of the Company's business, including its efforts to increase sales of OraQuick ® HIV, HCV and Molecular sample management solutions and its OraQuick ® In-Home HIV test and HIV Self-Test;
−Removed: • The Company's efforts to expand sales of its genomic and microbiome laboratory service offerings;
−Removed: • The Company's efforts to produce and commercialize its InteliSwab® Covid-19 Rapid Tests;
+Added: • The performance of the Company's business, including its efforts to increase sales of OraQuick ® HIV, HCV and sample management solutions and its OraQuick ® In-Home HIV test and HIV Self-Test;
• Future announcements concerning the Company and its products or services, including with respect to significant acquisitions, strategic collaborations and joint ventures;
−Removed: • Ability to achieve the expected benefits, enhanced revenue growth and synergies from strategic acquisitions;
+Added: • Ability to achieve the expected benefits, enhanced revenue growth and synergies from strategic acquisitions, including the Company's recent acquisition of Sherlock;
• Clinical results with respect to the Company's products or services or those of its competitors;
76 unchanged sentences
Similarly, if adequate financial, personnel, equipment or other resources are not available, the Company may be required to delay or scale back its business.
−Removed: The Company's operations will be adversely affected if its total revenue and gross profits do not correspondingly increase or if its technology, product, service, clinical and market development efforts are unsuccessful or delayed.
+Added: The Company's operations will be adversely affected if its total revenue and gross profits do not correspondingly increase or if its technology, product, service, clinical and market development
+Added: efforts are unsuccessful or delayed.
Furthermore, the Company's failure to successfully introduce new or enhanced products and services and develop new markets could have a material adverse effect on its business and prospects.
4 unchanged sentences
The Company's testing, or the subsequent testing by its independent public accounting firm, may reveal deficiencies in its internal control over financial reporting that are deemed to be material weaknesses.
−Removed: For instance, management identified a material weakness in the Company's internal control over financial reporting related to customer pricing in the revenue recognition process and concluded that its disclosure controls and procedures were not effective due to the existence of the material weakness as of September 30, 2023.
+Added: For instance, management identified a material weakness in the Company's internal control over financial reporting related to customer pricing in the revenue recognition process and concluded that its disclosure controls and procedures were not effective due to the existence of the material weakness as of September 30, 2023, which has since been remediated.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.
−Removed: During the fourth quarter of 2023, the Company implemented controls to validate accurate pricing in customer sales orders.
−Removed: As a result the material weakness was remediated as of December 31, 2023.
If the Company Loses Key Personnel or Is Unable to Attract and Retain Qualified Personnel as Necessary, Its Business Could be Harmed.
28 unchanged sentences
The Company Relies on Information Technology in Its Operations and Any Material Failure, Inadequacy, Interruption or Security Breach of that Technology Could Harm Its Ability to Efficiently Operate Its Business.
−Removed: The Company relies heavily on enterprise resource planning and other complex information technology systems across its operations and on the internet, including for management of inventory, processing and analyzing laboratory specimens, purchase orders, invoices, shipping, revenue and expense accounting, online business, consumer call support, and various other processes and transactions.
+Added: The Company relies heavily on enterprise resource planning and other complex information technology systems across its operations and on the internet, including for management of inventory, purchase orders, invoices, shipping, revenue and expense accounting, online business, consumer call support, and various other processes and transactions.
The Company's ability to effectively manage its business, coordinate the production, distribution and sale of its products, process and analyze specimens in its laboratories, respond to customer inquiries, and ensure the timely and accurate recording and disclosure of financial information depends significantly on the reliability and capacity of these systems and the internet.
−Removed: The failure of any of the foregoing systems to operate effectively, problems with transitioning to upgraded or replacement systems, or disruptions in the operation of the internet, could cause delays in product sales or the provision of laboratory services and reduced efficiency of the Company's operations.
+Added: The failure of any of the foregoing systems to operate effectively, problems with transitioning to upgraded or replacement systems, or disruptions in the operation of the internet, could cause delays in product sales and reduced efficiency of the Company's operations.
Significant expenditures could be required to remediate any such problem.
4 unchanged sentences
Cyber-attacks and other cybersecurity incidents such as ransomware, phishing, and social engineering attacks could result in unauthorized access to the Company's computer systems or its third-party IT service providers' systems and, if successful, misappropriate personal, sensitive, or confidential information.
−Removed: The Company has in the past and may in the future experience cybersecurity incidents.
+Added: As previously disclosed, the Company has in the past and may in the future experience cybersecurity incidents.
If successful, these attacks could lead to service interruptions, extortion, theft of confidential, personal or proprietary information, the compromise of data integrity or unauthorized information disclosure.
49 unchanged sentences
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.
−Removed: For example, on March 10 and March 12, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank, and Signature Bank and Silvergate Capital Corp, respectively, after each bank was unable to continue their operations.
+Added: For example, in early 2023, several financial institutions closed and were taken in receivership by the Federal Deposit Insurance Corporation.
Since then, additional financial institutions have experienced similar failures and have been placed into receivership.
3 unchanged sentences
While it is not possible at this time to predict the extent of the impact that the failure of these financial institutions or the high market volatility and instability of the banking sector could have on economic activity and the Company's business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact the Company's business, financial condition and results of operations.
+Added: Economic Volatility and Disruption Resulting from the COVID-19 Pandemic and any Future Pandemic and Health Crises Could Adversely Affect the Company’s Business, Financial Performance, Results of Operations, Cash Flow and Financial Condition or Those of Its Customers and Suppliers.
+Added: Global and U.S.
+Added: markets and economies have experienced extreme volatility and disruption following the COVID-19 pandemic.
+Added: Volatile economic conditions may occur again or continue in the future.
+Added: Impacts of the COVID-19 pandemic that the Company has or may experience in the future include, but are not limited to:
+Added: • a slowdown or stoppage in the supply chain of the raw materials and components used to manufacture its products;
+Added: • interruptions or delays in domestic and/or international shipment of its products to its distributors and customers;
+Added: • interruptions in normal operations of certain end-use customers that could result in reductions in demand for its products;
+Added: • disruptions to the Company’s operations, including a shutdown of its facilities or product lines;
+Added: restrictions on its operations and sales, marketing and distribution efforts;
+Added: and interruptions to its research and development, manufacturing, clinical/regulatory and other important business activities;
+Added: • shutdown or interruption of the Company’s manufacturing facilities due to contamination and costs incurred to clean and disinfect a facility following contamination;
+Added: • inefficiencies and increased costs in the Company’s production and shipping processes due to premium pay for manufacturing and certain other employees as well as social distancing and personal protective equipment requirements;
+Added: • limitations on employee resources and availability, including due to sickness, government restrictions, the desire of employees to avoid contact with large groups of people or mass transit disruptions;
+Added: • a fluctuation in foreign currency exchange rates or interest rates could result from market uncertainties;
+Added: • an increase in exposure to credit losses for customers adversely affected by the COVID-19 pandemic and any future health crises;
+Added: • an increase in regulatory restrictions or continued market volatility could hinder the Company’s ability to execute strategic business activities, including acquisitions.
+Added: These conditions could adversely affect the Company’s financial performance and condition or those of its customers and suppliers.
+Added: These circumstances could also adversely affect the Company’s access to liquidity needed to conduct or expand its business or conduct future acquisitions or make other discretionary investments.
+Added: Many of the Company’s customers rely on public funding provided by federal, state and local governments, and this funding has been and may continue to be reduced or deferred as a result of economic conditions or other factors.
+Added: These circumstances may adversely impact the Company’s customers and suppliers, which, in turn, could adversely affect their ability to purchase and/or distribute the Company’s products or supply it with necessary equipment, raw materials or components.
+Added: Any or all of these effects would have an adverse effect on the Company’s operations, business, financial condition and results of operations.
Terrorist Attacks, Natural Disasters, Public Health Crises, Political Unrest or Other Catastrophic Events Outside of the Company's Control May Adversely Affect Its Business.
1 unchanged sentence
These actions could adversely affect economic conditions both within and outside the United States and reduce demand for the Company's products.
−Removed: For example, the COVID-19 outbreak has led to, and for an unknown period of time will continue to lead to, disruptions in local, regional, national and global markets and economies affected thereby, including the United States.
−Removed: This outbreak has resulted in, and until fully resolved is likely to continue to result in, among other things:
−Removed: (i) restrictions on travel, government mandated social distancing measures, and the temporary closure of many corporate offices, retail stores, and manufacturing facilities and factories;
−Removed: (ii) significant disruption to the business of many companies, including the Company's customers and suppliers, as well as layoffs of employees;
−Removed: (iii) reduction or termination by public health and other customers of infectious disease testing programs, including for HIV and HCV, and a reallocation of personnel and monetary resources from these programs to programs intended to address COVID-19;
−Removed: (iv) reduction or termination of clinical and research studies by academic and other entities that use the Company's molecular sample management solutions and molecular laboratory services;
−Removed: and (v) rapidly evolving proposals and actions by state and federal governments to address the problems being experienced by markets, businesses and the economy in general, which may have unintended consequences or may not adequately address such problems.
−Removed: These events have disrupted, and threaten to continue to disrupt, the Company's normal operation, the operations of its customers and suppliers and eliminate, reduce or delay its customers’ ability to purchase and use its products and its suppliers’ ability to provide raw materials and finished products.
−Removed: Despite the Company's efforts to manage and mitigate the impact of these events on itself, it is impossible to predict the precise nature and consequences of these events, or of any political or policy decisions and regulatory changes occasioned by emerging events or uncertainty under applicable laws or regulations that impact the Company.
−Removed: It is clear that these types of events are impacting and will, for at least some time, continue to impact the Company's product development and operation and in many instances the impact
−Removed: may be adverse and may be material.
−Removed: Any potential impact to the Company's results of operations will depend to a large extent on future developments and new information that could emerge regarding the duration and severity of the COVID-19 pandemic and the actions taken by authorities and other entities to contain the spread or treat its impact, all of which are beyond the Company's control.
−Removed: These potential impacts, while uncertain, could adversely affect the Company's business and results of operation.
−Removed: In addition, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the United States and China, escalation of tensions between China and Taiwan, or escalation in conflict between Russia and Ukraine or between Israel and the various countries in the surrounding regions, including any resulting sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries against governmental or other entities in, for example, Russia, also could lead to disruption, instability and volatility in the global markets, which may have an adverse impact on the Company's business or ability to access the capital markets.
+Added: For example, the COVID-19 pandemic has caused disruptions in local, regional, national and global markets and economies, including the United States.
+Added: These events disrupted the Company's normal operation and the operations of its customers and suppliers.
+Added: In addition, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the United States and China, escalation of tensions between China and Taiwan, or escalation in conflict between Russia and Ukraine or the Israel-Hamas war, including any resulting sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries against governmental or other entities in, for example, Russia, also could lead to disruption, instability and volatility in the global markets, which may have an adverse impact on the Company's business or ability to access the capital markets.
+Added: As a result of the ongoing military conflict between Russia and Ukraine, the United States and other countries have imposed significant sanctions on Russia and could impose even wider sanctions.
+Added: Such sanctions could damage or disrupt international commerce and the global economy.
+Added: The Company cannot predict the broader or longer-term consequences of the conflict in Ukraine or Israel, or of the sanctions imposed to date, which could include embargoes, regional instability, geopolitical shifts, exchange rate fluctuations, financial market disruptions and economic recession.
+Added: Further, the conflict in Ukraine or Israel could exacerbate supply chain challenges, lead to an increase in cyberattacks, affect the global price and availability of key commodities, reduce the Company’s sales and earnings or otherwise have an adverse effect on its business and results of operations.
Various types of disasters, including earthquakes, fires, floods, riots, acts of terrorism and pandemics, may also affect the Company's manufacturing facilities and computer systems, and increase its cybersecurity risks.
3 unchanged sentences
Moreover, the Company may incur incremental costs following an unforeseen event which could adversely affect its results of operation.
−Removed: The Ongoing Conflict Between Russia and Ukraine, and the Israel-Hamas War, and the Related Implications Could Have a Material Adverse Effect on the Company's Business And Results Of Operations.
−Removed: As a result of the ongoing military conflict between Russia and Ukraine, the United States and other countries have imposed significant sanctions on Russia and could impose even wider sanctions.
−Removed: Such sanctions could damage or disrupt international commerce and the global economy.
−Removed: The Company cannot predict the broader or longer-term consequences of the conflict in Ukraine or Israel, or of the sanctions imposed to date, which could include embargoes, regional instability, geopolitical shifts, exchange rate fluctuations, financial market disruptions and economic recession.
−Removed: Further, the conflict in Ukraine or Israel could exacerbate supply chain challenges, lead to an increase in cyberattacks, affect the global price and availability of key commodities, reduce the Company's sales and earnings or otherwise have an adverse effect on its business and results of operations.
−Removed: In addition, the conflict between Russia and Ukraine and the Israel-Hamas war may have the effect of heightening other risks disclosed in this Annual Report, any of which could materially and adversely affect the Company's business and results of operations.
−Removed: Such risks include but are not limited to interruptions in the transportation channels for the manufacture and global distribution of the Company's products, heightened inflation, depressed levels of consumer and commercial spending, disruptions to its global technology infrastructure, adverse changes in international trade policies and relations, and the inability to implement and execute its business strategy.
−Removed: The Company is currently unable to predict the extent, nature or duration of any of these occurrences.
+Added: The Increasing Prevalence of AI-based Software Presents New Risks and Could Adversely Affect Our Business and Reputation.
+Added: AI-based software and software making use of AI functionality, which the Company uses in certain parts of its business, is increasingly being used in the healthcare industry, such as for research, marketing, and commercialization, and we expect to use technology that uses AI in the future.
+Added: As with many developing technologies, AI-based software presents risks and challenges.
+Added: For example, algorithms may be flawed;
+Added: data sets may be insufficient, of poor quality or contain biased information;
+Added: and inappropriate or controversial data practices could impair results.
+Added: If the analyses that AI-based software assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm.
+Added: Use of AI-based software may also lead to cybersecurity risks or the release of confidential proprietary information, including personal data, which may impact our ability to realize the benefit of our intellectual property or violate our internal policies, data protection laws or contractual requirements.
+Added: The use of AI-based software may also result in unauthorized access of personal data or the intellectual property of third parties.
+Added: Since the use of AI is
+Added: subject to new or evolving laws and regulations, compliance may impose operational costs and limit our ability to use AI-based software, and failure to comply may result in potential government actions, litigation, fines, penalties or adverse publicity.
Future Sales of Shares of the Company's Common Stock Could Adversely Affect the Trading Price of Its Common Stock and Its Ability to Raise Funds in New Equity Offerings.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.